SCHEMBL7514441

SCHEMBL7514441

CCc1ccccc1N.COc1ccc(Br)c(CN(CCc2ccccc2)C(=O)OC(C)(C)C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 3/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
LPAR1 Q92633 2/20 0.41
LPAR5 Q9H1C0 2/20 0.41
TDP1 Q9NUW8 1/20 0.40
TSHR P16473 3/20 0.39
HTR1A P08908 1/20 0.39
SLC6A4 P31645 1/20 0.39
ALOX5 P09917 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
HPGD P15428 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
HDAC1 Q13547 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6419488 0.93 KDM4E (0.48) KDM4EMEN1KMT2AALDH1A1CYP1A2
Ammonia Solution, Strong SCHEMBL7514434 0.87 KDM4E (0.44) KDM4EMEN1KMT2AALDH1A1CYP1A2
SCHEMBL6947777 0.82 KDM4E (0.48) KDM4EMEN1KMT2AALDH1A1CYP1A2
SCHEMBL6944991 0.79 KDM4E (0.46) KDM4EMEN1KMT2AALDH1A1CYP1A2
SCHEMBL6376540 0.78 HDAC1 (0.43) LPAR1LPAR5L3MBTL1PTGDR2HDAC1
SCHEMBL4719084 0.78 SSTR4 (0.46) KDM4EALDH1A1CYP1A2CYP3A4CYP2C19
SCHEMBL6378379 0.77 SLC7A5 (0.43) LPAR1LPAR5TDP1L3MBTL1HPGD
SCHEMBL4717219 0.75 SSTR4 (0.38) KDM4EMEN1KMT2AALDH1A1TSHR
Methane SCHEMBL27480452 0.75 L3MBTL1 (0.42) KDM4EMEN1KMT2AALDH1A1CYP1A2
SCHEMBL16468257 0.75 LPAR1 (0.47) MEN1KMT2AALDH1A1LPAR1LPAR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020032187-A1 Method for stimulating bone formation SMITHKLINE BEECHAM CORPORATION 2002-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032187-A1 Method for stimulating bone formation BMP2, BMP4, SOST KDM4E 4199/4885MEN1 2235/4885KMT2A 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.